Mobia Medical, Inc. IPO - What You Need to Know

Thinking about the Mobia Medical IPO? It is exciting to get in early, but let’s look at the facts in plain English before you invest.

1. What does this company do?

Mobia Medical created the Vivistim System. It is the only FDA-approved device that helps chronic stroke survivors regain movement in their arms and hands.

Think of it as a "brain-training" system. A small implant sends gentle pulses to the vagus nerve while a patient does physical therapy. This helps the brain "re-wire" itself. It has helped patients regain movement even decades after a stroke. The procedure takes 60 minutes, and 98% of patients and therapists report positive experiences. The system includes an implantable pulse generator, a lead wire, and a wireless transmitter for therapy sessions.

2. How do they make money?

Mobia is growing quickly. They brought in $32 million in 2025, more than double their $15.6 million in 2024.

However, they spend much more than they earn. In 2025, they spent over $72 million on operations, resulting in a $46.5 million loss. They are spending heavily on marketing, research, and hiring to get Vivistim into more hospitals. While they earn an 81% profit margin on the devices themselves, their high overhead costs mean they currently lose money overall.

3. What is the market opportunity?

There are roughly 10 million stroke survivors in the U.S. Mobia believes 1 million are prime candidates for their therapy. They see a potential $30 billion market. Because there is no standard treatment for chronic stroke recovery, Mobia is trying to create a new category of care. Their growth strategy focuses on adding more hospitals that can perform the procedure and expanding their sales team to educate doctors.

4. What are the main risks?

• The "Going Concern" Warning: The company has lost $157.8 million to date. Because they keep losing money, auditors have flagged "substantial doubt" about the company’s ability to stay in business unless they raise more cash or reach profitability soon.
• Growing Pains: Rapid growth is straining their management, supply chain, and financial record-keeping. They have identified "material weaknesses" in their internal financial controls.
• "Emerging Growth" Status: Mobia is using rules that allow them to provide less financial history and fewer executive pay disclosures than larger companies.
• Insurance Reliance: Their success depends on convincing insurance companies to pay for the Vivistim procedure. Without consistent coverage from private insurers and Medicare, the high cost of the device may limit its use.

5. The Details: Ticker and Exchange

Mobia Medical will list on the Nasdaq under the ticker "MOBI."

A final note: IPOs are volatile. Prices can swing wildly in the first few weeks. If you are considering an investment, ask yourself: Am I comfortable with the risk of a company that is currently losing money and faces significant regulatory and insurance hurdles? If the answer is no, it might be better to watch from the sidelines until they prove they can turn a profit.

Disclaimer: I am an AI, not a financial advisor. This guide is for informational purposes only and does not constitute financial advice. Always do your own research or consult with a professional before investing.